We isolated a novel protease that converts plasminogen to angiostatin-like fragments (BL-angiostatins) from a culture of Bacillus megaterium A9542 through a single-step chromatography on CM-cellulose. Although BL-MA failed to activate plasminogen, it increased urokinase-catalyzed activation of plasminogen caused by production of miniplasminogen, which is highly susceptible to activation. In addition, BL-MA was active in converting prourokinase, prothrombin, coagulation factor X, and protein C to their active forms. BL-MA enhanced both the clotting of human plasma and clot dissolution in the presence of prourokinase. Thus, BL-MA affects blood coagulation and fibrinolysis systems and can be used to produce angiostatin-like plasminogen fragments and active serine proteases of human plasma.
The plasminogen/plasmin system plays crucial roles not only in blood clot lysis but also in various physiological and pathological events including inflammation, tissue remodeling, tumor metastasis, and angiogenesis, where localized proteolysis is required (1) (2) (3) (4) (5) . Human plasminogen is a single-chain glycoprotein of 92 kDa consisting of an N-terminal peptide, five kringle domains, and a serine protease domain (6, 7) . Plasminogen is converted to the active enzyme plasmin by specific cleavage of the Arg 561 -Val 562 bond by tissue-type plasminogen activator or urokinase-type plasminogen activator (u-PA). 1 The resulting plasmin in turn cleaves the Lys 77 ) has a serine protease domain. Under certain circumstances, including tumor progression and inflammation, plasmin(ogen) undergoes proteolysis to form kringle-containing A-chain fragments, collectively called angiostatins (8 -13) . It is postulated that physiological formation of angiostatins involves partial disulfide reduction in plasminogen and cleavage of plasminogen by plasmin itself and/or other proteinases such as matrix metalloproteinases, metalloelastase, and cathepsin D that are derived from tumor cells or infiltrating macrophages (11, 14 -17) . Typical angiostatin consists of the first four kringle domains (K1-4) of plasmin (8, 18, 19) . Angiostatin K1-4 and its relatives, including K1-3, K1-4 1 ⁄2 and A 61 , inhibit the proliferation of vascular endothelial cells, which is a fundamental process in angiogenesis (8 -12) . Angiostatin suppresses both in situ and metastatic tumor growths in animal models (8, 11, 15, 18, 19) .
We discovered recently several low molecular mass modulators of plasminogen activation (non-lysine analog plasminogen modulators) (20 -26) . During these studies, we identified a bacterial protease that enhances u-PA-catalyzed activation of plasminogen. The protease cleaves plasminogen to form angiostatin-like fragments and miniplasminogen. This paper describes purification and characterization of the protease, designated bacillolysin MA (BL-MA).
EXPERIMENTAL PROCEDURES

Materials-
The following chemicals and proteins were from commercial sources. Val-Leu-Lys-pNA (H-Val-Leu-Lys-p-nitroanilide) was from Bachem (Bubendorf, Switzerland). FA-Gly-Leu-amide (3-(2-furylacryloyl)-Gly-Leu amide) and S2336 (pyroglutamyl-Pro-Arg-pNA) were from Sigma. Spectrozyme fXa (methoxycarbonyl-D-cyclohexylglycyl-Gly-ArgpNA), Spectrozyme UK (carbobenzoxy-L-␥-glutamyl-(␣-t-butoxy)-GlyArg-pNA), and Spectrozyme TH (H-D-hexahydrotyrosol-Ala-Arg-pNA) were from American Diagnostica (Greenwich, CT). Other synthetic peptide substrates used were from Peptide Institute (Osaka, Japan). Human high molecular mass two-chain u-PA was from JRC Pharmaceuticals (Kobe, Japan). Human factor X, human factor IX, human prothrombin, and human protein C were from Hematologic Technologies (Essex Junction, VT). Purified human pro-u-PA (with 0.23% intrinsic amidolytic activity toward Spectrozyme UK) was kindly provided by Mitsubishi Pharma, Osaka, Japan. Human plasminogen was affinity * This work was supported by a grant from the Mishima Kaiun Memorial Foundation. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
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¶ To whom correspondence should be addressed. Tel.: 81-42-367-5710; Fax: 81-42-367-5708; E-mail: hasumi@cc.tuat.ac.jp. 1 The abbreviations used are: u-PA, urokinase-type plasminogen activator; APTT, activated partial thromboplastin time; BCEC, bovine capillary endothelial cell; BL-angiostatin, angiostatin-like plasminogen fragment produced by BL-MA cleavage; BL-MA, bacillolysin MA; DMEM, Dulbecco's modified Eagle's medium; EGM, endothelial growth medium; FA-Gly-Leu-amide, 3-(2-furylacryloyl)-Gly-Leu amide; FCS, fetal calf serum; HUVEC, human umbilical vein endothelial cell; MCA, methylcoumarine amide; MES, 4-morpholineethanesulfonic acid; pNA, p-nitroanilide.
purified from human plasma (27) . Angiostatin K1-3 was purified by lysine-Sepharose affinity chromatography from porcine elastase-digested plasminogen as described by O'Reilly et al. (18) .
Assay for BL-MA Activity-For determination of amidolytic activity toward FA-Gly-Leu-amide, 300 nM BL-MA was incubated in TBS/T (50 mM Tris-HCl, 100 mM NaCl, and 0.01% (w/v) Tween 80, pH 7.4) containing 1 mM CaCl 2 and 30 M FA-Gly-Leu-amide at 25°C. The decrease in absorbance at 345 nm (cleavage at Gly-Leu) was monitored continuously for 3 min using a Hitachi model 320 spectrophotometer. Where indicated (see Fig. 2 ), varying temperatures and buffers (pH) were used. For determination of amidolytic activity toward other synthetic substrates, 300 nM BL-MA was incubated in TBS/T containing 1 mM CaCl 2 and appropriate substrate as indicated (20 -100 M) . After incubation at 37°C, the release of pNA or aminomethylcoumarin from the substrate was determined periodically by measuring absorbance at 405 nm using a Bio-Rad model 550 microplate reader or fluorescence at 450 nm using a Corona MTP-32 microplate reader with an excitation wavelength of 365 nm. For determination of proteolytic activity, BL-MA (0.1 nM to 37 M or concentrations shown in each experiment) was incubated with appropriate substrate protein solution (200 g/ml or concentrations given in each experiment) in TBS/T containing 1 mM CaCl 2 at 37°C for 60 min (or time shown in each experiment). After incubation, reaction mixture was resolved on reduced SDS-PAGE. The gels were stained with Coomassie Brilliant Blue R-250. In kinetic experiments, bands were quantified by densitometric scanning.
Production and Purification of BL-MA-Bacillus megaterium A9542 was isolated from a soil sample collected at Kokubunji, Tokyo, and deposited in International Patent Organism Depository at National Institute of Advanced Industrial Science and Technology, Tsukuba, Japan (accession code FRM P-18268). The bacterium was grown aerobically for 6 days at 28°C in medium consisting of 1% glucose, 3% corn starch, 1% soybean meal, 0.5% peptone, 0.5% yeast extract, 0.2% CaCO 3 , and 0.1% antifoam CB442, pH 7.0. After filtration, the 1,300-ml culture was diluted with 4,940 ml of water and 325 ml of isopropyl alcohol. The mixture was applied to a 200-ml CM-cellulose column equilibrated with MES and isopropyl alcohol (20 mM MES-NaOH and 5% (v/v) isopropyl alcohol, pH 6.5) at a flow rate of 15 ml/min. After washing the column with 800 ml of MES and isopropyl alcohol, BL-MA was eluted with 400 ml of MES and isopropyl alcohol containing 200 mM NaCl.
Identification of BL-MA Gene--Based on partial amino acid sequence of BL-MA and its similarity to NprM protein (28), a 323-bp DNA fragment was amplified by PCR using chromosomal DNA from B. megaterium A9542 as a template and two oligonucleotide primers F2 (5Ј-CTATTGGCTCAGGTAAA-3Ј, corresponding to nucleotides 927-943 of the B. megaterium ATCC14581 nprM gene; EMBL X61380) and R2 (5Ј-ATTATTGTAACCGCTGC-3Ј, nucleotides 1249 -1233 of nprM). The DNA fragment was sequenced with the primers F2 and R2. Subsequently, inverse PCR was carried out on HindIII-digested and religated chromosomal DNA from strain A9542 with primers F3Ј (5Ј-TATTATG-CAGGTGTGAC-3Ј, nucleotides 1159 -1175 of the gene for BL-MA, blma; DDBJ accession code AB193158) and R0 (5Ј-TTTACCTGAGC-CAATAG-3Ј, nucleotides 966 -950 of blma). The amplified 2.1-kb DNA fragment was sequenced with the relevant primers derived from the sequence of the BL-MA gene fragment. To obtain the upstream region of the BL-MA gene, we amplified and sequenced a 1.2-kb DNA fragment by inverse PCR using XbaI-digested and religated chromosomal DNA with primers For1 (5Ј-GTTGATGCTATTAGCGG-3Ј, nucleotides 759 -845 of blma) and R1 (5Ј-GTCAACTTGCTTCTGGC-3Ј, nucleotides 660 -644 of blma). Automated DNA sequencing was performed on doublestrand DNA templates by the dideoxynucleotide chain termination method using an Applied Biosystems model 373A sequencer. The nucleotide sequence of the gene for BL-MA (blma) was deposited at DDBJ under the accession code AB193158.
Assay for Activation of Serine Protease Zymogens-u-PA-catalyzed activation of plasminogen was assayed by determining Val-Leu-LyspNA hydrolysis. Human plasminogen (100 nM) was incubated at 37°C with human two-chain u-PA (50 -200 units/ml) and 100 M Val-LeuLys-pNA at 37°C in 50 l of TBS/T. BL-MA-catalyzed activation of pro-u-PA was assayed by incubating 20 nM human pro-u-PA with 0.73-73 nM BL-MA and 100 M Spectrozyme UK at 37°C in 50 l of TBS/T containing 1 mM CaCl 2 . Similarly, BL-MA-catalyzed activations of human factor X, human prothrombin, and human protein C were assayed at 37°C in 50 l of TBS/T containing 1 mM CaCl 2 using 20 nM zymogen, 1-500 nM BL-MA, and 100 M chromogenic substrate (Spectrozyme fXa, Spectrozyme TH, or S2336, respectively). The hydrolysis of the chromogenic substrates was monitored periodically at 405 nm.
Purification of Angiostatin-like Plasminogen Fragment (BL-Angiostatin) and Miniplasminogen-like Fragment Produced by BL-MA
Cleavage-BL-angiostatin and miniplasminogen-like fragment were purified by lysine-Sepharose chromatography as follows. Human plasminogen (2 M) was incubated with 16 nM BL-MA at 37°C for 60 min in 8 ml of TBS/T containing 1 mM CaCl 2 . After adding 220 l of 0.2 M EDTA to inactivate BL-MA, the mixture was applied to a 4.6 ϫ 50-mm lysine-Sepharose column equilibrated with 50 mM sodium phosphate, pH 7.4. After washing with the buffer containing 500 mM NaCl, BLangiostatin was eluted with 2 ml of 200 mM 6-aminohexanoic acid. Both the flow-through fraction (containing miniplasminogen-like fragment) and 6-aminohexanoic acid eluate were passed separately through a DEAE-Sepharose column. After being dialyzed against buffer (2 mM sodium phosphate, pH 7.4, and 15 mM NaCl), the resulting materials were lyophilized and dissolved in 1/10 volume of 0.01% Tween 80 (for miniplasminogen-like fragment) or water (for BL-angiostatin).
Determination of Protein Sequence-Proteins were resolved on SDS-PAGE and transferred to polyvinylidene difluoride membrane. The membrane was stained with Coomassie Brilliant Blue R-250, and a section of membrane was subjected to N-terminal amino acid sequence analysis on a model 476A protein sequencer (Applied Biosystems).
Radioiodination of Proteins-To a glass tube coated with 5 g of IODO-GEN, 10 l of 50 mM sodium phosphate, pH 7.4, 1 l of Na 125 I (0.1 mCi), and either 29.3 M plasminogen in 50 l of 50 mM sodium phosphate, pH 7.4, or 37 nM pro-u-PA in 50 l of 100 mM sodium phosphate, pH 6.0, were added successively. After standing on ice for 10 min, the mixture received 50 l of 500 mM sodium phosphate, pH 7.4, containing 0.01% Triton X-100. After 15 min at room temperature, a 100-l aliquot of the mixture was applied to a 0.9-ml Sephadex G-25 column equilibrated with TBS/T to remove free Na 125 I. Cell Culture-Bovine capillary endothelial cells (BCECs; obtained from ATCC) were maintained in DMEM containing 10% fetal calf serum (FCS). Human umbilical vein endothelial cells (HUVECs; obtained from Clonetics, San Diego) were grown in EGM (endothelial cell growth medium; Clonetics) containing 2% FCS. HT1080 cells and rat primary fibroblasts were maintained in DMEM and 10% FCS, and Lewis lung carcinoma cells and Chinese hamster ovary-K1 cells were grown in RPMI 1640/10% FCS.
Cell Proliferation Assay-The proliferation of endothelial cell was assayed as described previously (9, 11) with slight modifications. BCECs were dispersed in 0.05% trypsin and resuspended with DMEM and 10% FCS. Cells were seeded into gelatin-coated 24-well plates at 12,500 cells/500 l of DMEM and incubated at 37°C overnight. Medium was replaced by 250 l of DMEM and 5% FCS containing BL-angiostatin or angiostatin K1-3. After incubation for 20 min, 250 l of DMEM containing 2 ng/ml basic fibroblast growth factor was added and incubated for 3 days. Cells were dispersed in 100 l of 0.05% trypsin and counted using a hemocytometer.
In experiments using HUVECs, cells were dispersed in trypsin/ EDTA solution (Clonetics) and resuspended with EGM defective in human epidermal growth factor. Cells (2,500 cells in 100 l) were seeded into 96-well plates and incubated at 37°C overnight. Medium was replaced by 100 l of fresh medium containing BL-angiostatin or angiostatin K1-3. After incubation for 30 min, 100 l of EGM containing 20 ng/ml epidermal growth factor was added and incubated for 3 days. The ability of cells to reduce formazan-forming reagent (WST-1; Dojindo Laboratories, Kumamoto, Japan) was determined as an index of cell number (26) .
The growth of nonendothelial cells was assayed by a method similar to that employed for the assay for HUVEC proliferation, using respective growth medium.
Endothelial Cell Migration Assay-A modified Boyden chamber method was used (29) . Polycarbonate membrane with 8-m pores was coated with 15 g of fibronectin and placed over a 24-well culture plate containing 500 l of EGM supplemented with 0.1% bovine serum albumin and 10 ng/ml basic fibroblast growth factor. After 30 min, HUVECs that had been starved overnight in serum-and growth factor-free EGM and 0.1% bovine serum albumin were seeded into the upper chamber (1.1 ϫ 10 5 cells in 500 l of EGM containing 20 g/ml BL-angiostatin or angiostatin K1-3) and incubated for 5 h. Nonmigrated cells were scraped off the upper chamber using cotton swabs. Migrated cells were fixed with 70% ethanol for 30 min, stained with Giemsa for 30 min, and counted under a light microscope at a ϫ100 magnification.
Endothelial Both the medium and collagen gel contained 5% FCS, 5 ng/ml epidermal growth factor, and 10 g/ml either BL-angiostatin or angiostatin K1-3. After 24 h of incubation at 37°C, cultures were examined under a light microscope at a ϫ40 magnification. The length of tubes in three fields was measured. Plasma Clot Formation and Clot Dissolution-Activated partial thromboplastin time (APTT) was determined using citrated human platelet-poor plasma. Plasma (60 l) was mixed with 30 l of BL-MA (0 -600 nM in PBS (20 mM sodium phosphate and 150 mM NaCl, pH 7.4)) and 60 l of APTT reagent (Wako Pure Chemical, Osaka, Japan). After incubation for 2 min at 37°C, the mixture received 50 l of CaCl 2 (50 mM in saline) to initiate clotting reaction, which was monitored at 37°C using a NKK Hematracer 1 (Niko Bioscience, Tokyo, Japan). The course of plasma clot formation and clot dissolution was measured by thrombelastography on a TE-700 Clot Tracer (Erma, Tokyo, Japan). Citrated human plasma (300 l) was mixed with 20 l of BL-MA (1-8 M) in PBS and 20 l of either PBS or PBS containing 200 nM pro-u-PA. Plasma clot formation was initiated by adding 60 l of 133 mM CaCl 2 , and thrombelastogram was recorded at 37°C.
RESULTS
Purification and Primary Structure of BL-MA-B
. megaterium A9542 was selected from a screen for searching modulators of plasminogen activation, employing 1,040 strains of microorganisms. The bacteria produced an activity to convert plasminogen to angiostatin-like fragments and miniplasminogen-like fragments. By tracing this activity, we tried several chromatographic purifications and found that CM-cellulose chromatography was most effective. From 1,300 ml of culture supernatant, we obtained 34.1 mg of electrophoretically homogeneous preparation of BL-MA (apparent molecular mass of 35.3 kDa in reduced SDS-PAGE) through a single-step chromatography on a CM-cellulose column (Fig. 1A) . In this process, a 68.5-fold purification was achieved with a yield of 48% (Fig. 1B) .
The automated Edman degradation of the protein yielded VTGTNAIGSG as an N-terminal sequence (Fig. 1C) . The data base search suggested that the sequence was highly similar to an internal amino acid sequence deduced from nucleotide sequence of a protease gene, nprM, from B. megaterium ATCC 14581 (28) . So, we amplified the gene for BL-MA using primers corresponding to the obtained N-terminal sequence and 5Ј and 3Ј regions of nprM. The nucleotide sequencing of the resulting PCR-amplified DNA fragments indicated that sequence of the coding region of the gene for BL-MA had 97.1% identity compared with the coding sequence of the nprM. The deduced amino acid sequence of BL-MA revealed 10 differences in amino acid residues from that of nprM protein (Fig. 1D) . The amino acids at putative signal peptide cleavage site, propeptide cleavage site, zinc binding site, and active site in BL-MA were the same as those of NprM protein.
Characterization of Enzymatic Activity of BL-MA-To characterize the catalytic activity of BL-MA, we first examined various chromogenic and fluorogenic synthetic peptides for their susceptibility to hydrolysis by BL-MA. The enzyme failed to release pNA or aminomethylcoumarin from Val-Leu-LyspNA, pyroglutamyl-Pro-Arg-pNA, methoxycarbonyl-D-cyclohexylglycyl-Gly-Arg-pNA, carbobenzoxy-L-␥-glutamyl-(␣-tbutoxy)-Gly-Arg-pNA, H-D-hexahydrotyrosol-Ala-Arg-pNA, succinyl-Ala-Ala-Ala-pNA, Leu-pNA, benzoyl-Tyr-pNA, benzoyl-Arg-pNA, pyroglutamyl-Phe-Leu-pNA, t-butyloxycarbonyl-Val-Leu-Lys-MCA, t-butyloxycarbonyl-Glu-Lys-Lys-MCA, t-butyloxycarbonyl-Ile-Glu-Gly-Arg-MCA, Gly-Gly-Arg-MCA, benzyloxycarbonyl-Arg-Arg-MCA, benzyloxycarbonylPhe-Arg-MCA, and succinyl-Leu-Leu-Val-Tyr-MCA. However, FA-Gly-Leu-amide was hydrolyzed efficiently by BL-MA. Among the protein substrates tested, plasminogen, casein, and gelatin were partially degraded by BL-MA at 3.7 nM (enzyme: substrate ratio at 1:1,600 by weight), whereas cleavages of bovine serum albumin, ␣ 2 -plasmin inhibitor, ovalbumin, and hemoglobin were only observed at higher BL-MA concentrations (1.8 -37 M; enzyme:substrate ratio at 1:3.2 to 1:0.16 by weight). BL-MA-catalyzed plasminogen fragmentation was FIG. 1. Purification and primary structure of BL-MA. BL-MA was purified from a culture of B. megaterium A9542 through CM-cellulose chromatography. The purified enzyme (1 g) was resolved on reduced SDS-PAGE on a 10% gel (A). B is a summary of the purification. The N-terminal amino acid sequence of the purified protein is shown in C. D shows the amino acid sequence of BL-MA, deduced from the nucleotide sequence of its gene. Sequence 1, BL-MA; sequence 2, nprM. In sequence 2, only amino acids different from sequence 1 are shown. The residues 1-24 (italic), 24 -245, and 246 -562 (boldface) are putative signal peptide, propeptide, and mature enzyme, respectively. The underline represents the residues determined by Edman degradation. The residues 389 and 477 (boxes) are assigned to active center, and residues 388, 392, and 412 (double underline) are allocated to a zinc binding site from similarity (28) .
completely inhibited by 1 mM EDTA but not by 1 mM iodoacetic acid, 1 mM phenylmethanesulfonyl fluoride, 0.5 mM leupeptin, 0.5 mM pepstatin A, 0.5 mM antipain, 1 mM N-␣-tosyl-phenylalanine chloromethyl ketone, 5 M ␣ 2 -plasmin inhibitor, and 100 kallikrein inhibitor units/ml aprotinin.
Optimal catalytic conditions and enzyme stability were examined using FA-Gly-Leu-amide as a substrate. BL-MA had pH and temperature optima at pH 7.4 and 60°C, respectively (Fig. 2, A and B) . The enzyme activity was increased by CoCl 2 (by 1.8-fold at 0.3 mM) and reduced by ZnCl 2 (by 80% at 1 mM), whereas CaCl 2 did not affect activity at 0.08 -2.4 mM (Fig. 2C) . BL-MA kept its activity after treatment at 37°C for 60 min at pH 5 to 9, whereas the enzyme completely lost its activity by treatment at pH 4 and 11.7 ( Fig. 2A) . When BL-MA was treated at 70°C for 20 min, the enzyme activity was reduced by 65%, but the enzyme was stable at 25-60°C (Fig. 2B) .
The above data suggest that BL-MA is a neutral metalloproteinase. These results are consistent with the observation that the nucleotide sequence of the gene for BL-MA shows significant similarity to npr, a bacterial gene family of neutral metalloproteinase.
BL-MA-catalyzed Plasminogen Cleavage-BL-MA was active in cleaving 2 M human plasminogen at a concentration as low as 3.7 nM (enzyme:substrate ratio at ϳ 1:540 by mol) after incubation at 37°C for 60 min. Under these conditions, plasminogen gave three major fragments at 58.4 (fragment 1), 53.5 (fragment 2), and 45.9 kDa (fragment 4) in nonreduced SDS-PAGE (Fig. 3A) , which corresponded to bands at 65.4, 62.0, and 40.5 kDa, respectively, in reduced SDS-PAGE (Fig. 3B) . The BL-MA-catalyzed cleavage of plasminogen could be observed in 50% human serum milieu, although the efficiency was reduced by Ͼ100-fold (Fig. 3C ). Both fragments 1 and 2 had the same N-terminal sequence, initiating with Glu 1 of plasminogen (Fig.  3D ). Upon treatment with peptide-N 4 -(N-acetyl-␤-glucosaminyl)-asparagine amidase F, fragment 1 disappeared, and the intensity of the band for fragment 2 increased (Fig. 3E) . These results suggested that the difference in apparent molecular mass between the two fragments was caused by the difference in N-glycosylation, possibly at Asn 289 . Fragment 4 had Val 442 of plasminogen as an N terminus (Fig. 3D) (Fig. 3F) . The incubation of plasminogen with a higher concentration of BL-MA (37 nM) yielded additional two minor fragments (bands 3 and 5 in Fig.   3 , A and B), which had Phe 75 and Leu 449 of plasminogen as N termini, respectively (Fig. 3D) . Taken together, we propose possible structures of BL-MA-cleaved plasminogen in Fig. 3F . The kinetic measurements of the BL-MA-catalyzed cleavage at Ser 441 -Asn 791 were performed by measuring the generation of miniplasminogen-like fragment (fragment 4) using densitometric scanning of Coomassie Brilliant Blue-stained gels. The results showed that the plasminogen cleavage by BL-MA proceeded with a K m of 3.0 Ϯ 0.8 M and a k cat of 0.70 Ϯ 0.09 s Ϫ1 (Fig. 3G) .
Modulation of Plasminogen Activation by BL-MA-As shown in Fig. 4A , the BL-MA treatment of plasminogen did not generate plasmin activity, demonstrating that BL-MA itself was not a plasminogen activator. On the other hand, in the incubation of plasminogen with two-chain u-PA, the addition of BL-MA elevated the rate of plasminogen activation. Because BL-MA did not affect the enzymatic activity of two-chain u-PA (see below), one of possible mechanisms accounting for this result was that miniplasminogen-like molecule produced by BL-MA could be activated by two-chain u-PA with higher efficiency compared with plasminogen. As shown in Fig. 4B , the miniplasminogen-like fragment was activated by two-chain u-PA five times faster than plasminogen. The activation accompanied the formation of two-chain molecule (Fig. 4C) . Thus, the miniplasminogen-like molecule was biochemically functional.
Antiendothelial Activity of BL-Angiostatin-BL-angiostatin produced by the BL-MA-cleavage of plasminogen was purified by lysine-Sepharose chromatography (Fig. 5A ) and assayed for inhibition of proliferation, migration, and tube formation of vascular endothelial cells in culture. The BL-angiostatin preparation consisted mainly of fragments 1 and 2 (see Fig. 3A ), and the purity was 78% as judged from densitometric scanning of Coomassie Brilliant Blue R-250-stained gel. The major impurity was plasminogen (22%). BL-angiostatin inhibited the proliferation of BCECs by 37-44% at 1-10 g/ml (Fig. 5B) . BLangiostatin was also active in inhibiting the proliferation of HUVECs (Fig. 5C) but not of nonendothelial cells (Fig. 5D) . BL-angiostatin inhibited the migration of HUVECs by 56 Ϯ 5% (p Ͻ 0.01) at 10 g/ml (Fig. 5E ). Tube formation was suppressed by 39 Ϯ 12% (p Ͻ 0.05) in HUVEC cultures treated with 10 g/ml BL-angiostatin (Fig. 5F ). These activities of BL-angiostatin were slightly higher than those of K1-3 angiostatin.
BL-MA Cleavage of Other Plasma Serine Protease Zymogens-
The above experiments suggested that BL-MA cleaved the N-terminal side of an aliphatic or a hydrophobic amino acid residue. We next tested BL-MA for its ability to cleave other human plasma serine protease zymogens because many such   FIG. 2 . Characterization of amidolytic activity of BL-MA. The enzymatic activity of BL-MA was characterized using FA-Gly-Leu-amide as a substrate. A, 300 nM BL-MA was assayed for activity either at the indicated pH (open symbols) or at pH 7.4 after preincubation at the indicated pH for 20 min at 25°C (closed symbols). Buffers used were 100 mM sodium acetate (circles), 100 mM sodium phosphate (triangles), TBS/T (diamond), and 100 mM sodium borate (squares). All buffers contained 1 mM CaCl 2 . B, 300 nM BL-MA was assayed for activity either at the indicated temperature (E) or at 25°C after preincubation at the indicated temperature for 20 min at 25°C (•). In A and B, the concentration of BL-MA at preincubation was 3 M. C, 300 nM BL-MA was assayed in the presence of the indicated concentrations of CaCl 2 (•), ZnCl 2 (E), or CoCl 2 (OE) using TBS/T as a buffer. The results are shown as percent of control (incubation in the absence of metal ion). The control value in C was 4.50 Ϯ 0.80 mM/min (n ϭ 6). Other values represent the average of duplicate determinations.
FIG. 3. Characterization of plasminogen cleavage by BL-MA.
A, 2 M plasminogen (Plg) was treated with BL-MA at the indicated concentrations for 60 min at 37°C and then subjected to nonreduced SDS-PAGE on a 10% gel. The positions of plasminogen and its fragments (numbered arrowheads on the right) are shown. B, plasminogen treated with 37 nM BL-MA as in A was resolved on reduced SDS-PAGE on a 10% gel. The fragment numbers correspond to those in A. C, 125 I-plasminogen (100,000 cpm) was added to 50% (v/v) human serum, and the mixture was incubated with the indicated concentrations of BL-MA for 60 min at 37°C in a 10-l volume. After incubation, 90 l of water was added, and a 5-l aliquot was resolved on reduced SDS-PAGE on a 12.5% gel. D, the N-terminal amino acid sequence of bands 1-5 in A was determined by automated Edman degradation. E, 2.46 g of partially purified BL-angiostatin was resolved on reduced SDS-PAGE on a 7.5% gel either directly or after treatment with 47 units/ml peptide-N 4 -(N-acetyl-␤-glucosaminyl)-asparagine amidase F (PNGase F; Takara Bio) for 30 min at 37°C. F, possible structures of BL-MA-cleaved plasminogen fragments are shown schematically. A solid line represents a polypeptide chain, and a zigzag line denotes a sugar chain. The domain structure is represented as a circle or a box; K, kringle domain; Protease, serine protease domain. G, plasminogen at concentrations indicated was incubated with 37 nM BL-MA for 60 min at 37°C and resolved on reduced SDS-PAGE on a 10% gel, followed by staining with Coomassie Brilliant Blue R-250. The rate of the formation of miniplasminogen (corresponding to band 4 in B) was determined by comparing the intensities of band 4 with those of purified miniplasminogen. Double reciprocal plots for the BL-MA-catalyzed miniplasminogen formation (cleavage of plasminogen at Ser zymogens have aliphatic amino acids at the P1Ј position of activation cleavage. Among the zymogens tested, pro-u-PA, prothrombin, factor X, and protein C were enzymatically activated by BL-MA, whereas factor IX did not yield active enzyme although it was cleaved by BL-MA.
Pro-u-PA Cleavage-Pro-u-PA was sensitive to cleavage by BL-MA at BL-MA concentrations of 3.7-110 nM (enzyme:substrate ratio of 1:540 to 1:18 by mol). At BL-MA concentration of 3.7 nM, the cleavage occurred mainly at Lys 158 -Ile 159 , resulting in the production of fragments corresponding to A-chain (fragments 2 and 3) and B-chain (fragment 1) that can be produced by plasmin (Fig. 6, B and D) . At a higher BL-MA concentration (110 nM), an additional cleavage at Tyr 24 -Phe 25 occurred (Fig.  6, D and E) , resulting in the production of fragments 4 and 5 in Fig. 6B . At both BL-MA concentrations, the apparent molecular size of the resulting cleavage products was identical to that of pro-u-PA under nonreduced SDS-PAGE (Fig. 6A) , showing that every chain was connected by disulfide bridges. It should be noted that the A-chain fragments migrated as a doublet in reduced SDS-PAGE, although each pair has the same N-terminal sequence. The difference in molecular mass between both doublets was ϳ1.5 kDa. A possibility that the difference is the result of the difference in the C terminus of each pair was unlikely because, to account for such difference, additional cleavage should occur at a site proximal to Cys 148 that connects N-terminal domains (A-chain) with the catalytic domain (Bchain) by disulfide bridge between Cys 279 (such cleavage should dissociate A-chain and B-chain under nonreducing conditions). Rather, the difference might come from a difference in glycosylation in A-chain. About half of the pro-u-PA molecules have an O-linked sugar chain at Ser 138 , and the remaining half do not have sugar modification at this position. 2 Thus, the high and low molecular mass species of each pair may, respectively, represent A-chain (or its fragment) with or without O-linked sugar chain at Ser 138 (Fig. 6E) . Pro-u-PA cleavage by BL-MA was also observed in 50% serum milieu (Fig. 6C ). u-PA activity was generated in the incubation of pro-u-PA with BL-MA (Fig.  6F) . When 1 M pro-u-PA was treated with BL-MA for 60 min at 37°C and then assayed for amidolytic activity at a concentration of 20 nM, u-PA activity reached a plateau at a level comparable with that exerted by 20 nM two-chain u-PA (Fig.  6G) . BL-MA did not affect the activity of two-chain u-PA (data not shown). Therefore, the u-PA species produced by BL-MA, including the three-chain form, may have an activity comparable with two-chain u-PA. Kinetic parameters for the BL-MAcatalyzed generation of u-PA activity were as follows: K m 0.14 Ϯ 0.02 M and k cat 5.2 Ϯ 1.0 ϫ 10 Ϫ3 sec Ϫ1 (Fig. 6H) . Factor X Cleavage-Factor X was cleaved by BL-MA at relatively higher concentrations (30 -300 nM; enzyme:substrate ratio at 1:67 to 1:7 by mol) (Fig. 7, A and B) . The cleavage occurred at Asp 34 -Leu 35 and Arg 52 -Ile 53 of the heavy chain (Fig.  7, C and D) . The Arg 52 -Ile 53 bond is the site cleaved by factor IXa, and this cleavage leads to proenzyme activation. The enzyme activity, as determined using a chromogenic substrate for factor Xa, was generated in the incubation of factor X and BL-MA (Fig. 7E ) with a K m at 2.5 Ϯ 0.8 M and a k cat of 0.11 Ϯ 0.03 s Ϫ1 (Fig. 7F ). Prothrombin and Protein C Cleavages-BL-MA was effective in activating prothrombin and protein C. The concentration of 2 S. Kameyama, personal communication.
FIG. 5. Antiendothelial activity of BL-angiostatin.
A, 1 g of plasminogen (Plg) and 1 g of purified BL-angiostatin preparation (BL-AS) was resolved on nonreduced SDS-PAGE on a 10% gel. The proliferation of BCEC (B), HUVEC (C), and four nonendothelial cell lines (D) (HT, TH1080 cells; LLC, Lewis lung carcinoma; Fibro, rat fibroblasts; CHO, Chinese hamster ovary-K1 cells) was assayed in the absence (control) or presence of the indicated concentrations (B and C) or 10 g/ml (D) of BL-angiostatin or angiostatin K1-3. E, the migration of HUVEC was assayed in the absence (control) or presence of 10 g/ml BL-angiostatin or 10 g/ml K1-3. Each value represents the mean Ϯ S.D. from duplicate (B) or triplicate determinations (C-E). *, p Ͻ 0.05 and **, p Ͻ 0.01 by Student's t test. F, tube formation of HUVECs was assayed in the absence (control) or presence of 10 g/ml BL-angiostatin or K1-3. After incubation for 24 h, cells were examined for tube formation under a light microscope at a ϫ40 magnification.
BL-MA required for efficient activation was Ͼ20 nM for the activation of prothrombin (Fig. 8A) and Ͼ1 nM for protein C activation (Fig. 8B) .
Factor IX Cleavage-Factor IX is processed by BL-MA at very low concentrations (0.1-3 nM; enzyme:substrate ratio at 1:20,000 to 1:667 by mol) (Fig. 9, A and B) . The cleavage occurred at Lys 142 -Leu 143 and Asp 177 -Phe 178 (Fig. 9, C and D) . Both of the cleavage sites are 3 residues proximal to the sites cleaved by factor XIa. These cleavages did not cause enzymatic activation of factor IX (data not shown).
Enhancement by BL-MA of Plasma Clotting and Clot Dissolution-The clotting of citrated human plasma, as determined by the APTT test, was enhanced by BL-MA at 100 -200 nM. The clotting time was shortened by 37% (p Ͻ 0.05) at 200 nM (Fig.  10A) . Next, thrombelastography was used to monitor the course of plasma clotting after the addition CaCl 2 alone. The clot formation time was shortened markedly by BL-MA at 50 -400 nM (Fig.  10B) , whereas solidity of the clot (maximum amplitude) was only increased slightly (Fig. 10C) . Under these conditions, BL-MA did not cause significant dissolution of the clot during the 120-min incubation (data not shown). On the other hand, in plasma supplemented with 20 nM pro-u-PA, 200 nM BL-MA significantly enhanced the dissolution of clot (Fig. 10, D and E) . These results suggest that BL-MA promotes blood coagulation and enhances fibrinolysis where pro-u-PA is available.
DISCUSSION
In the present study, we isolated a novel bacterial protease, BL-MA, which converts human plasminogen to BL-angiostatin and activates several serine protease zymogens. BL-MA gene belongs to a family of neutral metalloproteinases designated npr. The gene for BL-MA is most similar to nprM (97.1% identity), which codes for a neutral metalloproteinase NprM (29) . The proteases belonging to the npr gene family have an activity cleaving proximal sites of peptidyl aliphatic residues (30) , although it has not been reported that these proteases specifically cleave plasminogen to form angiostatin-like fragments or activate coagulation and fibrinolytic enzymes.
Recently, Lijnen et al. (31) described a bacterial protease that converts plasminogen to angiostatin-like fragments. The protease (24k-endopeptidase) is not inhibited by EDTA, an enzymatic feature of the protease discriminating it from that of BL-MA. to inhibit proliferation, migration, and tube formation of vascular endothelial cells. These activities were similar to or more potent than angiostatin K1-3. The BL-angiostatin preparation used in this study mostly consists of A-chain fragments with the N-terminal peptide (Glu 1 -Lys 78 of plasminogen), whereas angiostatins lack the N-terminal peptide. Therefore, it is likely that the existence of the N-terminal peptide does not interfere with, but rather benefits, the antiendothelial activity. Because the N-terminal peptide contains 26 charged residues and 18 polar residues of 78 amino acid residues, it should confer hydrophilic nature on the BL-angiostatin compared with typical angiostatin K1-4. Angiostatins have been administered subcutaneously in many animal experiments. Some experiments were performed using insoluble angiostatin preparation (32) . The high solubility of BL-angiostatin (Ͼ10 mg/ml) has permitted us to perform in vivo evaluations of BL-angiostatin using intravenous injections. In these experiments, BL-angiostatin at a daily dose of 0.3 mg/kg significantly reduced the growth of subcutaneously implanted Lewis carcinoma in mice. 3 In addition to the production of BL-angiostatins, the cleavage of plasminogen by BL-MA affords miniplasminogen-like fragments and modulates the activation of plasminogen. BL-MA itself does not have a plasminogen activator activity, although it enhances the activation of plasminogen, catalyzed by two-chain u-PA. BL-MA does not affect the activity of u-PA, even though it causes the formation of three-chain form, which is assumed to be comparable with the two-chain form in activity (Fig. 6) . Miniplasminogen-like fragment is activated five times more efficiently by u-PA, and therefore, the BL-MA enhancement of plasminogen activation may be the result of the formation of miniplasminogen.
BL-MA is capable of activating some serine protease zymogens from human plasma. These include pro-u-PA, factor X, prothrombin, and protein C, which have an aliphatic residue at P1Ј site of activation cleavage. The cleavages of pro-u-PA and factor X occur at a position that is the same as the canonical activation cleavage site (Lys 158 -Ile 159 in pro-u-PA and Arg 52 -Ile 53 of the heavy chain in factor X), whereas cleavages in prothrombin and protein C remain undetermined because of the complexity of the resulting cleavage products. Interest- FIG. 7 . Characterization of factor X cleavage by BL-MA. Factor X (2 M) was treated with the indicated concentrations of BL-MA for 120 min at 37°C and then subjected to nonreduced (A) or reduced (B) SDS-PAGE on a 10% or a 12.5% gel, respectively. The positions of fragments (numbered arrowheads on the right), which include heavy (H) chain and light (L) chain of factor X, are shown. C, the N-terminal amino acid sequence of bands 1-4 in B was determined by automated Edman degradation. D, possible structures of BL-MA-cleaved factor X fragments are shown schematically as given in Fig. 3 . Gla, Gla domain; G1 and G2, epidermal growth factor-like domains. E, 20 nM factor X was incubated with 100 M Spectrozyme fXa and the indicated concentrations of BL-MA (in nM) at 37°C, and the release of pNA was monitored periodically during the incubation. F, factor X at the indicated concentrations was incubated with 400 M Spectrozyme fXa and 10 nM BL-MA at 37°C, and the release of pNA was monitored periodically during the incubation. The rate of generation of factor Xa activity (v) was obtained from the slope of A 405 versus t 2 plots. Double reciprocal plots of the results are shown. Each value represents the average of triplicate determinations (E and F). ingly, factor IX is cleaved by BL-MA at a site 3 residues proximal to the canonical activation cleavage site (Arg 180 -Ala 181 ), although this activation cleavage site has an aliphatic residue at the P1Ј position. Accordingly, the cleavage of factor IX by BL-MA does not result in activation of factor IX. It remains to be tested whether BL-MA-cleaved factor IX can be activated by factor XI by cleavage at Arg 180 -Ala 181 . The above findings that BL-MA activates both procoagulant factors (factor X and prothrombin) and anticoagulant or fibrinolytic factors (protein C and pro-u-PA, as well as u-PAcatalyzed plasminogen activation) suggest that BL-MA may modulate both coagulation and fibrinolytic reactions. Indeed, the clotting of citrated human plasma after the addition of CaCl 2 is promoted by BL-MA. Further, clotting time is shortened by BL-MA in the APTT test, in which plasma is pretreated with an APTT reagent that activates the intrinsic pathway (the generation of factor XIIa). The incubation of fibrinogen alone with BL-MA does not result in clot formation (data not shown). Thus, BL-MA may affect site(s) between factor XI activation and prothrombin activation in the coagulation cascade. In the presence of exogenously added pro-u-PA, but not in its absence, plasma clot dissolution is enhanced markedly by BL-MA. These results indicate that BL-MA is active in the plasma milieu in modulating both the coagulation and fibrinolysis system.
There are only a small number of reports that describe bacterial proteases that activate coagulation and fibrinolysis systems. Activation of pro-u-PA by a bacterial protease has not been reported previously, and the activation of factor X, prothrombin, and protein C has recently been demonstrated by arginine-specific cysteine proteases (gingipains) from Porphyromonas gingivalis, a causative bacterium of periodontitis (33) (34) (35) . Proteases from foreign sources are thought to be virulence factors involved in inflammatory events occurring at infected sites, where fibrin deposition is a common feature. On the other hand, some pathogenic bacteria utilize the host's plasminogen/ plasmin system as a means of tissue invasion (36) . Some invasive bacteria can use cell surface-associated plasmin to facilitate movement through tissue barriers, and several bacterial strains produce plasminogen activators, e.g. streptokinase and staphylokinase. However, it is unclear whether the BL-MAcatalyzed formation of BL-angiostatin and miniplasminogen as well as activation of pro-u-PA, protein C, prothrombin, and factor X plays any role in the behavior of B. megaterium because the bacterium has no obvious pathogenicity.
In conclusion, we have shown that BL-MA converts human plasminogen to BL-angiostatin and activates several serine protease zymogens. We also demonstrate that BL-MA affects blood coagulation and fibrinolysis systems and can be used to produce angiostatin-like plasminogen fragments and active serine proteases of human plasma. A recently developed novel process utilizing highly efficient immobilized BL-MA reactor to produce BL-angiostatin 3 enables evaluation of antitumor activity of native, soluble BL-angiostatin.
